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We describe a case of isolated primary laryngeal leishmaniasis in an immunocompetent Italian patient with a previous medical
history negative for visceral or cutaneous leishmaniasis, presenting with hoarseness. We also summarize the epidemiological,
clinical, and diagnostic features and the therapeutic management of other cases of laryngeal leishmaniasis in immunocompetent
subjects, described in the literature. Considering the insidious and nonspecific clinical presentation, the increasing number of
different forms of mild or underestimated immunosuppressive conditions, and the number of people travelling in endemic zones,
along with the ability of Leishmania amastigotes to survive for a long period in the body, we believe it is important for pathologists
and clinicians to be aware of this unusual form of leishmaniasis in order to avoid delayed recognition and treatment. The rarity of
the presentation and the lack of guidelines on mucosal leishmaniasis may contribute to the potential undiagnosed cases or delayed
diagnosis, the possible relapses, as well as the correct pharmacological and/or surgical therapeutic approach.
1. Introduction
Leishmaniasis is a zoonosis caused by protozoa of the genus
Leishmania [1] and normally transmitted by the bite of the
female Phlebotomus (and Lutzomiya) sandfly [2]. Extent and
localization of lesions depend both on parasite characteristics
and host immune response. Leishmaniasis can be clinically
classified into three forms: cutaneous leishmaniasis (CL),
visceral leishmaniasis (VL), and mucosal/mucocutaneous
leishmaniasis (ML) [3].
In leishmaniasis, larynx is more often involved during
ML, whenmucosal lesions, firstly localized in the nose and/or
oral cavity, may progressively descend the upper respiratory
tract and sometimes involve the laryngeal mucosa. This is
typical of Leishmania (L) braziliensis infection, which is
common in South America [4]. However, some cases of
primary laryngeal leishmaniasis, without previous or con-
temporary involvement of other sites, have been reported.
These reports have been associated with L. donovani and L.
infantum infection, which are typical of the Mediterranean
Basin, India, and Sub-Saharan Africa [2].
Here, we present a case of primary isolated laryngeal
leishmaniasis in an immunocompetent Italian patient and a
review of the literature.
2. Case Presentation
In July 2010, a 64-year-old Italian man presented to the
Division of Infectious Diseases of the Garibaldi-Nesima
Hospital of Catania with an 8-month history of hoarseness
and discomfort. He lived in Sicily and he had not travelled
outside Europe. His medical history was notable for chronic
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Figure 1: (a) Laryngoscopy showing the presence of two focal hard and whitish lesions of the true vocal cords; (b) significant improvement
of vocal cord lesions after treatment with liposomal amphotericine B.
obstructive pulmonary disease (COPD), diagnosed 20 years
before but never treated with corticosteroids, and hyperten-
sion. He also referred hypersensitivity to some unspecified
nonsteroidal anti-inflammatory drugs and to be a former
smoker (25 cigarettes/day).
On physical examination, no skin lesions were noted;
there was neither hepatosplenomegaly nor lymphadenopa-
thy. Laboratory tests were unremarkable. Results of HIV
serological tests were negative.
In December 2009, before coming to our institute, the
patient had already undergone fibroscopy and a laryngeal
biopsy because of his symptoms. Histological examination
had revealed mucosal inflammation and hyperplasia. On
the basis of these results, he had been treated with amox-
icillin. In July 2010, because of lack of clinical improve-
ment, a second laryngeal biopsy had been performed.
The samples were taken from both vocal cords. Laryn-
gostroboscopic examination showed two focal hard and
whitish lesions of the true vocal cords, which had marked
attitude to hyperadduction and defect of mucosal wave
(Figure 1(a)). Histological examination showed the presence
of chronic inflammatory tissue with a wide amount of
histiocytes, containing a large number of round parasites,
which were referable to amastigotes belonging to Leishmania
spp. (Figure 2). The results of polymerase chain reaction
(PCR) analysis were positive for L. donovani. Finally, the
patient was treated with liposomal amphotericine B at a dose
of 3mg/kg/per day for 7 days, after which he continued
liposomal amphotericine B (3mg/kg once a week) for 5
weeks. At the end of the therapy, the patient reached complete
recovery.
In June 2011, the patient was readmitted to our institu-
tion because of increasing dysphonia. A laryngeal biopsy,
done in May 2011, still showed the presence of intracellular
Leishmania amastigotes, as such the patient was treated with
a liposomal amphotericine B-based regimen, at a dose of
3mg/kg/per day for seven days and, subsequently, 3mg/kg
once a week for 5 weeks. At the end of this treatment, the
patient had resolution of dysphonia and, at present, he is
in good health. Repeat laryngoscopy showed a significant
improvement of vocal cord lesions (Figure 1(b)).
Figure 2: Histological examination of a laryngeal bioptic specimen,
showing the presence of Leishmania spp. amastigotes in histiocytes
(Giemsa ×400)
3. Review And Discussion
3.1. Case Definition. We report a case of isolated laryngeal
leishmaniasis in an immunocompetent patient, who pre-
sented to our Infectious Diseases Unit. We also review 15
previously reported cases from 14 articles (Table 1). Other
articles were discarded because they did not meet the follow-
ing criteria: (1) full description of the case; (2) absence of any
other lesion related to Leishmania infection; (3) absence of
local or systemic immunodeficiency; (4) access to English full
text or English abstract. Patients were considered immuno-
compromised in presence of known immune compromising
factors, such as viral infections, corticosteroid therapy, or
tumors.
4. Review of Published Works and Discussion
Sixteen cases [5–18] of laryngeal leishmaniasis are reviewed,
including the present report and fifteen previously published
cases. The median patient age was 53.5 years (interquartile
range 41.5–64 years), and 94% were men. Seven patients
(45%) lived in Italy, three (19%) in France, two (12%) in
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Spain, one (6%) in India, Pakistan, United Kingdom, and
Denmark, respectively. Three patients (19%) had a travel
history, respectively, around Europe, Spain, and France.
As for comorbidities, a history of smoke was reported
in six cases (37.5%); three patients (19%), including the one
in the present report, had COPD, one (6%) had type 2
diabetes mellitus, another patient (6%) had thyroid nodules.
The patient described here also had hypertension.
In eleven cases (69%) laryngeal lesions were localized in
vocal cords, in two subjects with a consensual involvement
of the subglottic region (12%), and in two others of arytenoid
cartilage (12%). Subglottic region was the exclusive localiza-
tion in a case (6%), as well as epiglottis (6%). In three cases
(19%) the exact site was not specified.
The most common symptom (8/16 patients, 50%) was
dysphonia, isolated (37.5%) or accompanied by dyspnea
(37.5%) or dysphagia (25%). Six subjects (37.5%) complained
of hoarseness, in one case associatedwith dyspnea and cough,
in another with dysphagia. Less common symptoms (6%
in each case) were odynophagia and weight loss. When
reported, duration of symptoms ranged between two and
eight months.
Histological exam was successful in all cases. Giemsa
stain was performed in six cases (37.5%), haematoxylin and
eosin staining in four cases (25%). Antileishmania antibodies
were positive in six cases (37.5%).
In differential diagnosis, neoplasia was considered in five
cases (31%), histoplasmosis in two cases (12%); tuberculosis,
toxoplasmosis, and unspecific infectionwere each considered
in one case (6%).
Identification of Leishmania spp. was made in seven cases
(45%): L infantumwas identified in three cases, by culture and
isoenzyme analysis or PCR, in four others L. donovani was
isolated by PCR or immunoperoxidase analysis. In a case, a
generic diagnosis of infection by Leishmania spp. was made
by PCR.
In seven cases (45%), therapy was performed with lipo-
somal amphotericine B, in five cases (31%) with meglumine
antimoniate, and in two cases (12%) with surgery. After
treatment, twelve patients (75%) clinically recovered and one
(6%) only partially recovered.
Isolated laryngeal leishmaniasis has been related with L.
donovani and L. infantum infection [2, 19, 20]. Indeed, to
our knowledge cases of isolated laryngeal leishmaniasis asso-
ciated with L. braziliensis infection have not been reported
so far. It could mean that only some strains belonging to L.
donovani complex are able to adapt themselves to electively
live in the laryngeal tissue. Otherwise, the final site of lesions
may be determined by the effectiveness of the host immune
response against Leishmania. In this case, laryngeal lesions
would mirror the capability of macrophages to confine the
disease.
Leishmaniasis is transmitted by sandfly bite [1], but it
appears unlikely to hypothesize a direct injection of protozoa
in the laryngeal mucosa. More probably, Leishmania (free or
carried by macrophagic cells) may reach the laryngeal tissue
by lymphatics and bloodstream, after being inoculated in
more accessible sites. Unfortunately, the site of injection is
generally undetectable.
The localization of Leishmania in the laryngeal mucosa
is promoted by local or systemic immunodeficiency, for
example, HIV infection [21] and corticosteroid therapy [22].
In immunocompetent patients, the absence of any docu-
mented immunodeficiency, such as in our case report and
reviewed cases, suggests the need to speculate about other
risk factors. Aliaga and colleagues supposed that the lower
temperature of the upper aerodigestive tract might help the
survival of adapted Leishmania strains [3]. Inflammation of
the upper respiratory tract, associated with smoke [8, 11, 16–
18] or chronic respiratory diseases [14, 18], could also play
an important role. Infected macrophages may localize to the
larynx as a result of local constant inflammation.
In isolated laryngeal leishmaniasis, laryngeal lesions are
not specific, as well as symptoms. In fact, they may mimic
many inflammatory and neoplastic diseases. Diagnosis is
usually further complicated by the absence of any docu-
mented history of CL. Furthermore, comorbidities are often
misleading for physicians because, at first glance, symptoms
may be easily referred to comorbidities, such as in the
case described by Guddo and colleagues, who attributed
patient’s symptoms to COPD [14]. As a consequence, also
considering the low incidence of this atypical localization,
laryngeal leishmaniasis is hardly evaluated in differential
diagnosis by physicians. However, the spread of Leishma-
nia vectors in nonendemic zones [19] and the increasing
number of people travelling in endemic zones suggest to
suspect leishmaniasis as a possible explanation for laryngeal
symptoms. Moreover, because of the ability of protozoal
amastigotes to survive for a long time in human body [1, 4],
leishmaniasis has to be suspected even if the patient had
visited or lived in endemic zones many years before. Grant
and colleagues described a case of isolated mucosal leish-
maniasis diagnosed sixteen years after the probable infection
[23].
Suspected leishmaniasis needs laboratory tests to be con-
firmed. Histological evaluation of biopsies is usually able to
confirm diagnosis [20]. Nevertheless, our case report shows
that it sometimes fails to detect Leishmania amastigotes.
Probably, before performing a histological examination, the
physician should inform the pathologist about his suspicion
in order to help him in identifying protozoa. Other exams,
like leishmanin skin test (LST) and the detection of antileish-
mania antibodies, can only support diagnosis. Instead, PCR is
a highly sensitive and specific molecular method in detecting
the presence of LeishmaniaDNA and identifying the species.
Unfortunately, PCR is not always available [20].
Pentavalent antimonials (sodium stibogluconate and
meglumine antimoniate) and liposomal amphotericine B
are the most used drugs for leishmaniasis; for VL, their
recommended doses are, respectively, 20mg/kg/day for 28
days and 3–5mg/kg/day over a 3–6 days period, up to a
total dose of 18–21mg/kg [24]. Unfortunately, little evidence
is available for the treatment of laryngeal leishmaniasis,
because of the limited number of reported cases, which
makes it difficult to establish themost appropriate therapeutic
approach. The role of surgery for laryngeal leishmaniasis is
currently undefined, because, again, available evidence does
not allow to evaluate if the surgical option (alone or together
6 Case Reports in Infectious Diseases
with medical treatment) may adequately work for laryngeal
leishmaniasis.
Timing of followup is another controversial point; all but
one of the cases were characterized by clinical recovery and
no relapses, but timing of followup was not always reported,
and it is unclear if the absence of relapses 8–12 months after
treatment is enough to rule out the risk of reactivation. In
fact, after treatment for leishmaniasis, relapsesmay occur [4].
In two cases of isolated laryngeal leishmaniasis, immuno-
suppressed patients developed VL after successful treatment
[12, 21]. Our case report shows that relapses are possible also
in immunocompetent patients maybe because of the inability
of the immune system to effectively control infection and
eliminate protozoa.
5. Conclusion
There are some important clinical lessons that can be drawn
from the existing case literature and are reinforced by our
case report; the first message is that, even if rare, primary
isolated laryngeal leishmaniasis may occur in immunocom-
petent subjects, even in the absence of previous visceral,
cutaneous, or mucocutaneous leishmaniasis, and represent
an underestimated cause of laryngeal symptoms. Physicians
should include leishmaniasis in their diagnostic schedule,
especially if the patient has lived or travelled in endemic
zones. Early diagnosis is crucial, as leishmaniasis is a treatable
disease, whose natural history may be heavily changed by
proper recognition and treatment. PCR is the gold standard
to confirm the presence of protozoa but, unfortunately, it is
not routinely available. Accessibility to PCR testing should
be implemented, because it represents the most sensitive and
specific diagnostic tool in our hands.
Considering the insidious and nonspecific clinical pre-
sentation, the increasing number of different forms of
immunosuppression, and the number of people travelling
in endemic zones, along with the ability of Leishmania
amastigotes to survive for a long period in the body, we
believe it is important for physicians to consider leishma-
niasis as a possible cause of laryngeal symptoms, even in
immunocompetent subjects.
Finally, more research is needed to shed some light on
the mechanisms behind immunity to Leishmania in order
to explain how laryngeal leishmaniasis may occur even in
the absence of evident immune compromising risk factors.
More importantly, a therapeutic algorithm, pharmacological,
surgical, or combined, has never been investigated, as well
as the first or second line regimen, doses, and duration of
treatment. Furthermore, the possibility of relapses has to be
kept in consideration.
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